Who is sponsoring NCT05453071?

NCT05453071 is sponsored by Hacettepe University.

What drugs are being tested in NCT05453071?

Interventions in NCT05453071: Cognitive Exercise Therapy Approach (BETY).

What condition does NCT05453071 study?

NCT05453071 studies Systemic Sclerosis.

Is NCT05453071 still recruiting?

NCT05453071 is currently completed. Last updated 10 July 2023.

Last reviewed 2023-07-10 · How we verify

NCT05453071

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Cognitive Exercise Therapy Approach in Individuals With Systemic Sclerosis

Completed NA Last updated 10 July 2023

What this trial tests

NA trial testing Cognitive Exercise Therapy Approach (BETY) in Systemic Sclerosis in 37 participants. Completed in 2 November 2022.

Timeline

2 February 2022

Primary endpoint
15 March 2022

2 November 2022

Quick facts

Lead sponsor	Hacettepe University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	37
Start date	2 February 2022
Primary completion	15 March 2022
Estimated completion	2 November 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Cognitive Exercise Therapy Approach (BETY)

Conditions studied

Systemic Sclerosis — all drugs for Systemic Sclerosis →

Sponsor

Hacettepe University

Who can join

Adults 18 to 65, any sex, with Systemic Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the effects of Cognitive Exercise Therapy Approach (BETY) on vascularization, muscle strength, functionality, anti-inflammatory and biopsychosocial status in individuals with systemic sclerosis and to present a named exercise model for this disease group with objective results.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Do functionality, strength, vascularization, inflammatory and biopsychosocial status improve by biopsychosocial model-based exercise in SSc?
Tüfekçi O, Ünal E, Aktaş BE, Tan AA, et al · · 2025 · cited 4× · PMID 39018183 · DOI 10.1093/rheumatology/keae365

Verify or expand the search:

Other trials of Cognitive Exercise Therapy Approach (BETY)

Trials testing the same drug.

NCT06398210 — Investigation of the Effectiveness of Cognitive Exercise Therapy Approach in Patients With Primary Sjögren's Syndrome · NA · completed

Other recruiting trials for Systemic Sclerosis

Currently open trials in the same condition.

NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07295847 — A Study of AZD0120 in Autoimmune Diseases · Phase 1 · recruiting

Other Hacettepe University trials

Trials by the same sponsor.

NCT07522060 — Early Functional Response as a Predictor of Clinical Outcomes in Hand Rehabilitation: A Prospective Feasibility Study Us · not yet recruiting
NCT07390162 — The Effect of Changes in the Frequency of Endotracheal Tube Repositioning in Intensive Care Units on the Prevention of O · NA · not yet recruiting
NCT07579676 — DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF THE NEUROCOGNITIVE UPPER EXTREMITY TESTS: A RELIABILITY AND VALIDITY STUDY · not yet recruiting
NCT07524842 — Clinical Performance of Three Different Restorative Materials · NA · not yet recruiting
NCT07439861 — The Effect of Cognitive Dual-Task on Athletic Performance Parameters in Volleyball Players With and Without Chronic Ankl · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05453071 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hacettepe University
Last refreshed: 10 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05453071.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing